FOLH1 and prostate neoplasm: In vivo studies revealed that probe 24 could specifically activate in PSMA-positive tumors rather than PSMA-negative tumors (Figure 24D), showing its potential for fluorescence-guided accurate and complete resection of prostate tumors.